Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate

Gloria N. Mattiuzzi, Jorge E. Cortes, Moshe Talpaz, James Reuben, Mary Beth Rios, Jianjin Shan, Dimitrios Kontoyiannis, Francis J. Giles, Issam Raad, Srdan Verstovsek, Alessandra Ferrajoli, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Purpose: Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy. Patients and Methods: From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of Leukemia and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. Sixteen patients developed VZV infection. Charts and follow-up information of were reviewed and analyzed. Results: Sixteen patients (2%) developed a VZV infection [15 episodes of herpes zoster (HZ), 1 varicella]. The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection, except for time from diagnosis of CML to imatinib (median: 55 versus 25 months, P = 0.0056) and the number of prior therapies (3 versus 1, P < 0.001). All patients received therapy with antiviral agents with good response. Six patients developed postherpetic neuralgia. Conclusions: Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection. VZV infection is more frequent with longer duration of CML disease and with prior therapy, does not disseminate, responds well to therapy, and does not mandate a recommendation for HZ prophylaxis in such patients.

Original languageEnglish (US)
Pages (from-to)976-980
Number of pages5
JournalClinical Cancer Research
Volume9
Issue number3
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Human Herpesvirus 3
Virus Diseases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Herpes Zoster
Therapeutics
Infection
Leukemia, Myeloid, Chronic Phase
Postherpetic Neuralgia
Imatinib Mesylate
Chickenpox
Stem Cell Transplantation
Antiviral Agents
Leukemia
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mattiuzzi, G. N., Cortes, J. E., Talpaz, M., Reuben, J., Rios, M. B., Shan, J., ... Kantarjian, H. M. (2003). Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clinical Cancer Research, 9(3), 976-980.

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. / Mattiuzzi, Gloria N.; Cortes, Jorge E.; Talpaz, Moshe; Reuben, James; Rios, Mary Beth; Shan, Jianjin; Kontoyiannis, Dimitrios; Giles, Francis J.; Raad, Issam; Verstovsek, Srdan; Ferrajoli, Alessandra; Kantarjian, Hagop M.

In: Clinical Cancer Research, Vol. 9, No. 3, 01.03.2003, p. 976-980.

Research output: Contribution to journalArticle

Mattiuzzi, GN, Cortes, JE, Talpaz, M, Reuben, J, Rios, MB, Shan, J, Kontoyiannis, D, Giles, FJ, Raad, I, Verstovsek, S, Ferrajoli, A & Kantarjian, HM 2003, 'Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate', Clinical Cancer Research, vol. 9, no. 3, pp. 976-980.
Mattiuzzi, Gloria N. ; Cortes, Jorge E. ; Talpaz, Moshe ; Reuben, James ; Rios, Mary Beth ; Shan, Jianjin ; Kontoyiannis, Dimitrios ; Giles, Francis J. ; Raad, Issam ; Verstovsek, Srdan ; Ferrajoli, Alessandra ; Kantarjian, Hagop M. / Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 3. pp. 976-980.
@article{59b873789d94487fa730352c7fee0819,
title = "Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate",
abstract = "Purpose: Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy. Patients and Methods: From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of Leukemia and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. Sixteen patients developed VZV infection. Charts and follow-up information of were reviewed and analyzed. Results: Sixteen patients (2{\%}) developed a VZV infection [15 episodes of herpes zoster (HZ), 1 varicella]. The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection, except for time from diagnosis of CML to imatinib (median: 55 versus 25 months, P = 0.0056) and the number of prior therapies (3 versus 1, P < 0.001). All patients received therapy with antiviral agents with good response. Six patients developed postherpetic neuralgia. Conclusions: Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection. VZV infection is more frequent with longer duration of CML disease and with prior therapy, does not disseminate, responds well to therapy, and does not mandate a recommendation for HZ prophylaxis in such patients.",
author = "Mattiuzzi, {Gloria N.} and Cortes, {Jorge E.} and Moshe Talpaz and James Reuben and Rios, {Mary Beth} and Jianjin Shan and Dimitrios Kontoyiannis and Giles, {Francis J.} and Issam Raad and Srdan Verstovsek and Alessandra Ferrajoli and Kantarjian, {Hagop M.}",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "9",
pages = "976--980",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate

AU - Mattiuzzi, Gloria N.

AU - Cortes, Jorge E.

AU - Talpaz, Moshe

AU - Reuben, James

AU - Rios, Mary Beth

AU - Shan, Jianjin

AU - Kontoyiannis, Dimitrios

AU - Giles, Francis J.

AU - Raad, Issam

AU - Verstovsek, Srdan

AU - Ferrajoli, Alessandra

AU - Kantarjian, Hagop M.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Purpose: Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy. Patients and Methods: From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of Leukemia and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. Sixteen patients developed VZV infection. Charts and follow-up information of were reviewed and analyzed. Results: Sixteen patients (2%) developed a VZV infection [15 episodes of herpes zoster (HZ), 1 varicella]. The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection, except for time from diagnosis of CML to imatinib (median: 55 versus 25 months, P = 0.0056) and the number of prior therapies (3 versus 1, P < 0.001). All patients received therapy with antiviral agents with good response. Six patients developed postherpetic neuralgia. Conclusions: Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection. VZV infection is more frequent with longer duration of CML disease and with prior therapy, does not disseminate, responds well to therapy, and does not mandate a recommendation for HZ prophylaxis in such patients.

AB - Purpose: Infection with Varicella-Zoster virus (VZV) is an exceptionally rare complication of chronic myelogenous leukemia (CML) without stem cell transplantation. We report 16 patients with CML who developed VZV infection during imatinib mesylate therapy. Patients and Methods: From July 1998 until February 2002, 771 patients were included in 11 imatinib mesylate studies for all CML phases in the Departments of Leukemia and Bioimmunotherapy at The University of Texas M. D. Anderson Cancer Center. Sixteen patients developed VZV infection. Charts and follow-up information of were reviewed and analyzed. Results: Sixteen patients (2%) developed a VZV infection [15 episodes of herpes zoster (HZ), 1 varicella]. The baseline characteristics of the 16 patients with infection do not differ significantly from those who did not develop VZV infection, except for time from diagnosis of CML to imatinib (median: 55 versus 25 months, P = 0.0056) and the number of prior therapies (3 versus 1, P < 0.001). All patients received therapy with antiviral agents with good response. Six patients developed postherpetic neuralgia. Conclusions: Our results suggest that imatinib therapy in CML is associated with low incidence of HZ infection. VZV infection is more frequent with longer duration of CML disease and with prior therapy, does not disseminate, responds well to therapy, and does not mandate a recommendation for HZ prophylaxis in such patients.

UR - http://www.scopus.com/inward/record.url?scp=0037341414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037341414&partnerID=8YFLogxK

M3 - Article

C2 - 12631595

AN - SCOPUS:0037341414

VL - 9

SP - 976

EP - 980

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -